139 related articles for article (PubMed ID: 3599241)
1. Ureteral carcinoma in situ after successful intravesical therapy for superficial bladder tumors: incidence, possible pathogenesis and management.
Herr HW; Whitmore WF
J Urol; 1987 Aug; 138(2):292-4. PubMed ID: 3599241
[TBL] [Abstract][Full Text] [Related]
2. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor.
Coplen DE; Marcus MD; Myers JA; Ratliff TL; Catalona WJ
J Urol; 1990 Sep; 144(3):652-7. PubMed ID: 2388321
[TBL] [Abstract][Full Text] [Related]
3. Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder.
Herr HW; Pinsky CM; Whitmore WF; Sogani PC; Oettgen HF; Melamed MR
J Urol; 1986 Feb; 135(2):265-7. PubMed ID: 3511284
[TBL] [Abstract][Full Text] [Related]
4. The management of superficial bladder tumors and carcinoma in situ with intravesical bacillus Calmette-Guerin.
deKernion JB; Huang MY; Lindner A; Smith RB; Kaufman JJ
J Urol; 1985 Apr; 133(4):598-601. PubMed ID: 3981707
[TBL] [Abstract][Full Text] [Related]
5. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.
Kelley DR; Ratliff TL; Catalona WJ; Shapiro A; Lage JM; Bauer WC; Haaff EO; Dresner SM
J Urol; 1985 Jul; 134(1):48-53. PubMed ID: 3892051
[TBL] [Abstract][Full Text] [Related]
6. Analysis of early failures after intravesical instillation therapy with bacille Calmette-Guérin for carcinoma in situ of the bladder.
Merz VW; Marth D; Kraft R; Ackermann DK; Zingg EJ; Studer UE
Br J Urol; 1995 Feb; 75(2):180-4. PubMed ID: 7850322
[TBL] [Abstract][Full Text] [Related]
7. Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors.
Kavoussi LR; Torrence RJ; Gillen DP; Hudson MA; Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
J Urol; 1988 May; 139(5):935-40. PubMed ID: 3361667
[TBL] [Abstract][Full Text] [Related]
8. Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.
Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
J Urol; 1986 Oct; 136(4):820-4. PubMed ID: 3761438
[TBL] [Abstract][Full Text] [Related]
9. Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors.
Hudson MA; Yuan JJ; Catalona WJ; Ratliff TL
J Urol; 1990 Dec; 144(6):1362-4. PubMed ID: 2231927
[TBL] [Abstract][Full Text] [Related]
10. Long-term results of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer.
Sarosdy MF; Lamm DL
J Urol; 1989 Sep; 142(3):719-22. PubMed ID: 2769847
[TBL] [Abstract][Full Text] [Related]
11. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression.
Herr HW; Badalament RA; Amato DA; Laudone VP; Fair WR; Whitmore WF
J Urol; 1989 Jan; 141(1):22-9. PubMed ID: 2908949
[TBL] [Abstract][Full Text] [Related]
12. Intravesical bacillus Calmette-Guerin therapy for in situ transitional cell carcinoma involving the prostatic urethra.
Bretton PR; Herr HW; Whitmore WF; Badalament RA; Kimmel M; Provet J; Oettgen HF; Melamed MR; Fair WR
J Urol; 1989 Apr; 141(4):853-6. PubMed ID: 2926879
[TBL] [Abstract][Full Text] [Related]
13. Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial.
Hudson MA; Ratliff TL; Gillen DP; Haaff EO; Dresner SM; Catalona WJ
J Urol; 1987 Aug; 138(2):295-8. PubMed ID: 3298694
[TBL] [Abstract][Full Text] [Related]
14. Upper tract transitional cell carcinoma following treatment of superficial bladder cancer with BCG.
Miller EB; Eure GR; Schellhammer PF
Urology; 1993 Jul; 42(1):26-30. PubMed ID: 8328123
[TBL] [Abstract][Full Text] [Related]
15. Bacillus Calmette-Guerin immunotherapy for bladder cancer.
Lamm DL
J Urol; 1985 Jul; 134(1):40-7. PubMed ID: 3892050
[TBL] [Abstract][Full Text] [Related]
16. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
Lamm DL; DeHaven JI; Shriver J; Sarosdy MF
J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691
[TBL] [Abstract][Full Text] [Related]
17. Retrospective study of efficacy of intravesical BCG alone in treatment of superficial bladder cancer.
Mydlo JH; Usher SM; Camacho F; Freed S
Urology; 1986 Sep; 28(3):173-5. PubMed ID: 3750596
[TBL] [Abstract][Full Text] [Related]
18. Positive urinary cytology following a complete response to intravesical bacillus Calmette-Guerin therapy: pattern of recurrence.
Schwalb MD; Herr HW; Sogani PC; Russo P; Sheinfeld J; Fair WR
J Urol; 1994 Aug; 152(2 Pt 1):382-7. PubMed ID: 8015076
[TBL] [Abstract][Full Text] [Related]
19. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer.
Catalona WJ; Hudson MA; Gillen DP; Andriole GL; Ratliff TL
J Urol; 1987 Feb; 137(2):220-4. PubMed ID: 3806806
[TBL] [Abstract][Full Text] [Related]
20. Monitoring intravesical bacillus Calmette-Guerin treatment of superficial bladder carcinoma by postoperative urinary cytology.
Badalament RA; Gay H; Cibas ES; Herr HW; Whitmore WF; Fair WR; Melamed MR
J Urol; 1987 Oct; 138(4):763-5. PubMed ID: 3656528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
